Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 750
- Registration Number
- NCT00000651
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00002371
- Locations
- 🇺🇸
Harbor UCLA Med Ctr, Torrance, California, United States
🇺🇸SUNY at Stony Brook / Division of Infectious Diseases, Stony Brook, New York, United States
🇨🇦Montreal Gen Hosp / Div of Clin Immuno and Allergy, Montreal, Quebec, Canada
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 48
- Registration Number
- NCT00001113
- Locations
- 🇺🇸
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00002376
- Locations
- 🇺🇸
Kaiser Foundation Hospital, San Francisco, California, United States
A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT00002034
- Locations
- 🇺🇸
Dr Alfred F Burnside Jr, Columbia, South Carolina, United States
🇺🇸SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇨🇦Southern Alberta HIV Clinic / Foothills Hosp, Calgary, Alberta, Canada
A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002006
- Locations
- 🇺🇸
Natl Cancer Institute, Bethesda, Maryland, United States
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 325
- Registration Number
- NCT00002436
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Boston City Hosp / FGH-1, Boston, Massachusetts, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 320
- Registration Number
- NCT00000678
- Locations
- 🇺🇸
Graduate Hosp, Philadelphia, Pennsylvania, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Davies Med Ctr, San Francisco, California, United States
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT00000649
- Locations
- 🇺🇸
Univ of Massachusetts, Worcester, Massachusetts, United States
🇺🇸Cooper Green Hosp, Birmingham, Alabama, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002044
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.